Can Medra’s AI-powered lab scientists finally close the feedback loop in drug discovery?
Medra raises $52M to build AI-driven lab robots that run, learn, and optimize experiments. Learn how this startup is redefining drug discovery.
NiKang Therapeutics unveils NKT5097 as dual CDK2/4 degrader for solid tumor strategy
NiKang Therapeutics’ NKT5097 enters Phase 1 as a dual CDK2/4 degrader aiming to overcome breast cancer resistance. Explore what this strategy changes.
FDA re-approves USAntibiotics’ Augmentin XR, reviving domestic antibiotic access and setting CNPV precedent
FDA re-approves Augmentin XR under new priority program, restoring key antibiotic and signaling a turning point in U.S. drug supply strategy. Read more.
Can Guardant Health and Trial Library fix the clinical trial inclusion gap with AI and genomics?
Guardant Health and Trial Library team up to improve cancer trial access using AI and genomic data. Discover how this could reshape enrollment and equity in oncology.
What makes Prilenia’s PREVAiLS trial different from past ALS failures
FDA clears Prilenia’s PREVAiLS ALS trial. Can pridopidine validate neuroprotection and shift the treatment paradigm? Read the full analysis here.
Can Pfizer reposition TUKYSA as a first-line maintenance option after HER2CLIMB-05?
Pfizer’s tucatinib combo extends progression-free survival in HER2+ metastatic breast cancer. Find out what HER2CLIMB-05 means for frontline maintenance therapy.
Can IDE574 reshape breast and lung cancer treatment by targeting KAT6 and KAT7?
IDEAYA Biosciences files IND for IDE574, a KAT6/7 inhibitor for breast and lung cancer. Learn how this new class may change epigenetic treatment strategies.
Can Ascletis’ denifanstat reshape acne treatment by targeting fatty acid synthesis?
Ascletis’ acne drug denifanstat advances with NDA acceptance in China. Explore how FASN targeting could disrupt acne care and redefine systemic treatments.
Novo Nordisk finalizes $5.2bn Akero deal to expand in advanced MASH care
Novo Nordisk has acquired Akero Therapeutics for up to $5.2 billion to advance efruxifermin, its Phase 3 MASH asset. Find out what this means for liver care.
Could Novartis change the ITP playbook with just four doses of ianalumab?
Can four doses replace chronic ITP therapy? Find out how Novartis’ ianalumab performed in the VAYHIT2 trial and what it could mean for autoimmune care.